Published September 2018 | Version v1
Journal article

Citrus bioflavonoids dipeptidyl peptidase-4 inhibition compared with gliptin antidiabetic medications

  • 1. School of Medicine, University of Tasmania, Hobart, TAS, Australia 7000 (United States)
  • 2. Department of Diabetes & Endocrinology, Royal Hobart Hospital, Hobart, TAS, 7000 (Australia)
  • 3. School of Community Health, Charles Sturt University, Albury, NSW, 2640 (Australia)
  • 4. Central Science Laboratory, University of Tasmania, Hobart, TAS, 7005 (Australia)
  • 5. School of Life Sciences, La Trobe University, Bundoora, VIC, 3086 (Australia)

Description

Highlights: • The citrus bioflavonoids may possess dipeptidyl peptidase-4 (DPP-4) inhibition activity similar to gliptins. • Various citrus bioflavonoids may have a variable DPP-4 inhibition activity. • The measurement of the DPP-4 inhibition activity can be done using DPP-4 inhibition kit. • Commercial citrus bioflavonoid supplements contain various citrus bioflavonoids with different DPP-4 inhibition activities. This study compared dipeptidyl peptidase-4 (DPP-4) inhibitory activity of citrus bioflavonoid nutraceuticals compared with three gliptins. Citrus bioflavonoid standards and three commercially available citrus bioflavonoid supplements (Thompson's Super Bioflavonoid Complex®(SB), Ethical Nutrients Bioflavonoids Plus Vitamin C®(EN), and Country Life Citrus Bioflavonoids and Rutin®(CB)) were considered in this study. Ultra-performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) analysis was undertaken to identify and quantitate the citrus bioflavonoids present in each supplement. The DPP-4 inhibitory activity was determined by fluorometric assay. All of the tested individual citrus flavonoids demonstrated DPP-4 inhibitory activity, with IC50 values ranging from 485 μM (rutin) to 5700 μM (hesperitin and eriodictyol). Similarly, the flavonoid supplements had IC50 values of 16.9 mg/mL (EN), 3.44 mg/mL (SB) and 2.72 mg/mL (CB). These values compare with gliptin IC50 values of 0.684 μM (sitagliptin), 0.707 μM (saxagliptin) and 2.286 μM (vildagliptin). The supplement flavonoid content varied from 11.98% (CB) to 5.26% (EN) and 14.51% (SB) of tablet mass, corresponding to daily flavonoid doses of around 300, 150 and 400 mg, respectively, with CB and SB containing rutin at levels of 7.0% and 7.5% of tablet mass, respectively. While our data demonstrated that citrus bioflavonoid based supplements do possess DPP-4 inhibitory activity, they are several orders of magnitude less potent than gliptins. Further studies using higher concentrations of citrus bioflavonoids, as well as investigations into antioxidant properties which may add additional benefit are warranted.

Availability note (English)

Available from http://dx.doi.org/10.1016/j.bbrc.2018.04.156

Additional details

Identifiers

DOI
10.1016/j.bbrc.2018.04.156;
PII
S0006291X18309379;

Publishing Information

Journal Title
Biochemical and Biophysical Research Communications
Journal Volume
503
Journal Issue
1
Journal Page Range
p. 21-25
ISSN
0006-291X
CODEN
BBRCA9

INIS

Country of Publication
United States
Country of Input or Organization
International Atomic Energy Agency (IAEA)
INIS RN
53054190
Subject category
S60: APPLIED LIFE SCIENCES;
Descriptors DEI
ANTIOXIDANTS; BIOFLAVONOIDS; CITRUS; FLAVONOIDS
Descriptors DEC
MAGNOLIOPHYTA; MAGNOLIOPSIDA; ORGANIC COMPOUNDS; ORGANIC OXYGEN COMPOUNDS; PLANTS; VITAMINS

Optional Information

Copyright
Copyright (c) 2018 Elsevier Inc. All rights reserved.